Boston Children's Hospital and Harvard Medical School provided preclinical data for a therapy related to ODD.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Boston Children's Hospital and Harvard Medical School provided preclinical data for a therapy related to ODD.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- A study author is based in Johns Hopkins School of Medicine, and the research is connected to Baltimore, now involving the FDA for drug approval.
- Lakefront, in collaboration with Gilead, received Orphan Drug Designation from the FDA for gamgertamig, with trials active globally.